Comparative Pharmacology
Head-to-head clinical analysis: STERI STAT versus SYNALAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STERI STAT versus SYNALAR.
STERI-STAT vs SYNALAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis by blocking peptide bond formation and translocation.
Corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
Adults: 1 gram intravenously every 8 hours infused over 60 minutes.
Apply a thin layer to affected area twice daily. Max 60 g/week.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min).
Terminal elimination half-life: 1-2 hours (topical use); 3-4 hours (systemic absorption after topical application to large areas or occluded skin). Clinical context: short half-life allows once- or twice-daily dosing.
Renal excretion of unchanged drug accounts for approximately 95% of elimination; biliary/fecal elimination is minimal (<5%).
Renal: <1% as unchanged drug; biliary/fecal: minimal; primarily hepatic metabolism with metabolites excreted renally.
Category C
Category C
Corticosteroid
Corticosteroid